Mañana me encontrareis en...Premio Virgilio Palacio 2013 / Día Mundial de la Lucha contra el SIDA 2014

8 campañas gráficas que te ayudan a prevenir el VIH / Sida (I)

Algunas de las campañas de publicidad más creativas, ya que exploran el lado sexual y el morbo, son las que se crean para prevenir el contagio del VIH y SIDA. Estas campañas ayudan a concientizar a las personas sobre el uso del condón y sobre razonar antes de emprender a tener relaciones sexuales.

El día Internacional del SIDA es el 1 de diciembre, pero no sólo ese día se debe de hablar sobre la prevención del VIH, ya que es un virus que está en incremento y el prevenirlo es muy fácil, pero la falta de cultura, educación e información sobre prevención de enfermedades sexuales en las personas es muy baja. 

 Hay campañas de publicidad que se han dedicado a eso, a “educar” a personas sobre las consecuencias y diferentes métodos para prevenir el SIDA. Campañas que con mucha creatividad, relatan historias verídicas y crudas, e incluso algunas veces divertidas, con el fin de inspirar y despertar el interés de las personas. (Ver)

Campaña: One Life 
Eslogan: Each time you sleep with someone, you also sleep with his past. Get tested for HIV. 
Agencia de publicidad: Bleublancrouge, Montréal, Canada

Juán Goytisolo*, Premio Cervantes 2014, y el SIDA.

El recientemente nominado Premio Cervantes 2014 no es ajeno al tema que proximamente conmemoraremos, Dia Mundial del SIDA.

Rosalia Cornejo-Parriego (Pennsylvania State University) publica en Arizona Journal of  Hispanic Cultural Studies:

"Del discurso de la enfermedad al discurso de la identidad en Juan Goytisolo"


Del artículo:

Sin duda alguna, el discurso clinico goytisoliano llega a su culminación en Las virtudes del pájaro solitario (1988) donde el Sida y la obra de San Juan de la Cruz comparten el protagonismo. 

En esta novela, clínicas de desintoxicación, balnearios y psiquiátricos constituyen algunos de los espacios fundamentales donde "frailes comisarios malsines enfermeras doctores" se dan la mano. La caída de uno de los personajes—elemento misterioso de la trama—conduce a una enumeración minuciosa de las consecuencias médicas que tal acontecimiento acarrea: reacciones psicosomáticas, traslado al quirófano, radiografía craneana y consulta con el director del equipo de traumatología (47). La narración se vuelve más cruda cuando se refiere específicamente al Sida. 

No sólo alude al certificado de seronegatividad (147), sino que también enumera los "síntomas agoreros del mal," "vómitos, diarreas, eritemas, manchas, bocas descarnadas" (123; 129) que presagian la "descomposición súbita de nuestro organismo en carroña" (16). La mirada médica revela una particular crueldad en la descripción de la agonía de la Seminarista: 

…capsulada en su celdilla hermética, separada de las demás enfermas, cociéndose en la hediondez de su propia baba, visión de esperpento, demacrada, bubosa, toda uñas y pelo, arañaba furiosamente las paredes de su burbuja, quería salir y apestar el aire que respirábamos, los doctores habían puesto una cruz en sus organigramas y ya ni la atendían, sólo una enfermera con escafandra le servía la comida por un agujero ... La vimos descomponerse poco a poco como una papilla fungosa....(34) 

La actualidad del Sida junto a su centralidad argumental le confiere especial dramatismo a Virtudes y la convierte, en el contexto de la narrativa goytisoliana, en la novela paradigmática de la enfermedad—no en vano la devastadora "plaga" irrumpe en la primera página de la novela. 
Su encarnación, por otra parte, en la figura mítico-folclórica de la muerte sembrando la cizaña, el "pajarraco" del cuadro de Félicien Rops, lleva a cabo una verdadera mitologización de la enfermedad…

A modo de reconocimiento y homenaje...

(*) Juán Goytisolo 

Ratón de biblioteca: S.I.D.A. ¿Maldición bíblica o enfermedad letal? / A.Cardin & A. de Fluvia (Editores)

'We saw our first AIDS patient in July 1980. 

He was a 33-year-old homosexual, 

originally from West Germany, 

who had lived for the past three years in Haiti, 

where he'd worked as a chef," 

Dr. Donna Mildvan*, chief of infectious diseases 

Beth Israel Medical Center

Biblioteca #CasaMaza

"A pesar de la intermitente alarma de los periodicos y del miedo que recorre a las comunidades de otros paises, el SIDA sigue siendo contemplado en España con indiferencia cuando no con audaz menosprecio.
Bien es verdad que la incidencia de dicha enfermedad ni alcanza aún cifras alarmantes pero también es cierto que van sumados ya 18 casos y ni se han tomado aún medidas preventivas, ni se han establecido centros de control y análisis de datos, ni resulta siquiera posible localizar equipos o dispensarios donde se atiendan, informen y evaluen los casos sospechosos."

Son reflexiones (premonitorias?) que, en contraportada, Alberto Cardín (Villamayor, Asturias 15.1.1948 / Barcelona 26.1.1992), como editor, coloca en esta recopilacón de textos facilitados por Armand Fluviá (archivador de material "gay"). Corria 1985...

Cinco años atrás (1980), Donna Mildvan* (amiga en Venezuela y Nueva York) ya reportaba su primer caso, un varón homosexual de 33 años.

Dos después (1982), ella en Nueva York / yo en California, Donna me advertía del riesgo. El AIDS/SIDA había dejado de ser una enfermedad de "gays". Habían diagnosticado también la enfermedad en niños, mujeres y hombres heterosexuales...

En los 80´s las farmacias españolas, de manera irresponsable, negaban la venta de inyectadoras a quien no viniera con receta médica...

Años más, siete, vivió Alberto Cardín.

"El Sida lo mató, aunque al sobrevenirle el mal ni se replegó ni abandonó el estudio y sus múltiples ocupaciones, todo lo contrario, se convirtió en uno de los más destacados investigadores del fenómeno, que divulgó en artículos y libros como 'Sida, ¿maldición bíblica o enfermedad letal?' (1985), escrito en colaboración con Armand de Fluviá, o 'El estigma en la sombra, la atípica marginalidad de los homosexuales portadores de sida' (1989), o en el prólogo que le puso, en 1991, a 'Sida, enfoques alternativos', que quería ser, como dijo, «una propuesta informativa sobre posibilidades reales de terapias alternativas», a fin de que se hiciera una «gestión responsable de la enfermedad por parte de aquellos que la padecen». (Más)


Años menos, veinticinco, con Alberto Cardín coincidía muchas veces en el tren de carbón (Ferrocarriles Económicos de Asturias), él en Villamayor/yo en Arriondas, camino de Gijón, al Colegio de la Inmaculada (PPJesuitas) donde estudiábamos.
En pocos días celebraré allá las "bodas de oro" de mi promoción. En la del año próximo (la suya) el no estará...

 

(*) Donna Mildvan, 
chief of Infectious Disease at Beth Israel Hospital on Manhattan's Lower East Side, had been studying sexually transmitted intestinal infections in gay men since the mid-1970s. Her initial interest in the subject was piqued by an unusual, puzzling case of protozoal infection, "unheard of" in a patient with no travel history. She and her colleague Dan William, a gay physician working on sexually transmitted diseases at New York City's Department of Health, assembled a cohort of sexually active gay men to study enteric diseases. 

In the late 1970s, Mildvan noticed lymphadenopathy or swollen lymph glands in a number of them. Neither she nor other doctors she consulted could make a diagnosis. Lymph node biopsies came back negative. Here was another medical mystery, one that Mildvan set aside for want of sufficient data. In 1980, an event occurred that only heightened her perplexity.(Más)

Act Up: VIH Empoderamiento ciudadano

 

The Access to medicine Index 2014

"...al fin de cuentas, 

las empresas farmacéuticas no se dedican 

a la actividad empresarial 

empujadas por la bondad dentro de sus corazones, 

y no hay dinero que ganar en la prevención 

y curación de las enfermedades de los pobres." 

Ebola y desigualdad

Joseph E. Stiglitz, Univ.de Columbia 

Premio Nobel de Economía 2001

 
The Access to Medicine Index (descargar) independently ranks pharmaceutical companies’ efforts to improve access to medicine in developing countries. Funded by the Bill & Melinda Gates Foundation and the UK and Dutch governments, the Index has been published every two years since 2008.

Ver:

 The Access to Medicine Index 2010

 The Access to Medicine Index 2012

The access to medicine problem is multifaceted, and responsibility for tackling it lies with many different actors - governments, NGOs, academia, pharmaceutical companies, finance institutions and multilateral organisations such as the WHO. As manufacturers and developers of life-saving products, pharmaceutical companies clearly have a crucial role to play.

 Click sobre imagen para ampliar

Why an Index? 

The Index publicly recognises companies for their investments in access to medicine, raising awareness of relevant issues within pharmaceutical companies and providing them with a transparent means by which they can assess, monitor and improve their own performance as well as their public and investment profiles. Consistent iterations of the Index highlight industry trends and provide a basis for multi-stakeholder dialogue and solution building.

Five companies are developing more than half of the products in the pipeline for developing countries.

The top 20 pharmaceutical companies are developing 327 relevant products, with only five companies (Novartis, J&J, GSK, AbbVie and Sanofi) accounting for more than half the pipeline and more than half the products targeting only five diseases. 

Compared to 2012, pricing strategies are increasingly tailored, as more companies take account of socioeconomic factors, such as ability to pay. Importantly, more companies are setting different prices for different segments of national populations.

How Much Does it Cost to Develop a Drug? What do you Think? / Ed Silverman en TWSJ

For years, there has been intense debate over what it costs to develop a new drug. And tomorrow, one think tank hopes to put the issue to rest. Of course, this remains to be seen. 

Drug makers maintain the true cost should reflect the investment in not only the hits, but the misses. In other words, the pharmaceutical industry says the expense needed to successfully concoct any one medicine should incorporate the costs of the many failures that occur along the way. 

Conversely, consumer advocates and some academics, among others, regularly contest industry estimates, which have been rising over the years. As they see it, the numbers proffered by drug makers mask a combination of irrelevant and overstated expenses. And these estimates, they go on to argue, are unfairly used to justify rising prices. 

For these reasons, arguments are likely to continue. Nonetheless, the Tufts Center for the Study of Drug Development on Tuesday will release a report that will take yet another stab at determining the true cost. The last time the think tank offered an estimate was in 2003, when it calculated the cost to develop a drug at $802 million. The findings were published in the Journal of Health Economics.

Ver:

FORBES: El "sorprendente" costo de la invención de nuevos medicamentos.

So what might the latest number from Tufts look like? Already, the betting has begun. A forum run by one consumer advocacy group is asking participants to guess and, so far, their answers have ranged from about $1.1 billion to $2.5 billion. 

Since 2003, various estimates have suggested the cost has increased significantly. Two years ago, for instance, the cost was estimated at $1.5 billion by the Office of Health Economics, a consulting firm that received an unrestricted grant from AstraZeneca to compile its report. The Tufts analysis, however, remains widely cited as a benchmark. How does the Tufts Center calculate the cost? The non-profit think tank relies on data supplied, in part, by the pharmaceutical industry as well as other sources. For those who are interested, the methodology will be released along with the bottom-line calculations. We should note, by the way, that the Tufts Center is funded, in part, by the pharmaceutical industry. 

So what do you think the number will be? No, there is no prize for the person who guesses correctly, but this is as good a time as any to think it over.n (Ver)

Ver también:

Desmitificando el costo de desarrollo de un nuevo medicamento.

The next pharma Blockbusters...Merck, BMS, AstraZeneca, Roche.

  
Ver 
y descargar informe

In September, Merck's PD-1 blocker Keytruda (pembrolizumab) received accelerated approval from the FDA to treat melanoma and the company is researching the drug against non-small cell lung cancer (NSCLC) and other indications. In its World Preview 2014 Outlook report, EvaluatePharma forecasts Keytruda sales of $4.06 billion by 2020.

That's a great start, but it's unclear whether Merck's advantage will hold out over the long haul. The competition will be fierce in the PD-1/PD-L1 space. With the huge potential market, this could be the equivalent of the Oklahoma land rush for the usual pharma titans. However, Stephanie Hawthorne, senior director at Kantar Health, notes that, for now in melanoma, Merck is in the driver's seat compared to BMS's PD-1 inhibitor Opdivo (nivolumab), which is a few months (or possibly longer) behind Keytruda in the US. 

"It's a big advantage for Merck being first-to-market," says Hawthorne. "Based on the available data, they both look really efficacious, and they're fairly well tolerated compared to Yervoy. BMS's saving grace might be the combination of Opdivo and Yervoy they are studying. The survival data we've seen for it so far is really impressive, and that could trump Merck's lead." 

Hawthorne's point was underscored in late September when BMS released data at the European Society for Medical Oncology (ESMO) showing that Opdivo achieved a 32% response rate against advanced melanoma in patients who had previously been treated with Yervoy. The control group, which received traditional chemo, had an 11 % response. 

While Keytruda was first in the US, Opdivo was approved for melanoma in Japan in July, under a deal with BMS partner Ono Pharmaceuticals. The ESMO data will only support BMS's showing in the US. The FDA has given Opdivo fast track designation in NSCLC, melanoma, and renal cell carcinoma (RCC) and breakthrough therapy designation for Hodgkin's lymphoma. In September, BMS announced that both the FDA and European Medicines Agency (EMA) have accepted Opdivo for accelerated review for melanoma. The FDA PDUFA date is March 30, 2015. 

"Opdivo is the most valuable pipeline drug in development at the moment," says Lisa Urquhart, editor of Evaluate's editorial team, EP Vantage. "The data from studies is showing some impressive advances in both overall survival and disease progression." 

EvaluatePharma pegs Opdivo's potential sales at $6 billion by 2020. The company believes Opdivo could be approved for melanoma in the US next year. Meanwhile, Hawthorne expects approval for the Opdivo/Yervoy combination in early 2016. 

That's in melanoma. Opdivo may even have a more clear-cut advantage in being first-to-market for NSCLC, where BMS has already submitted its drug for approval while Merck is still completing Phase III trials. 

 Genentech/Roche's PD-L1 offering, MPDL3280A (RG-7446), is in trials for NSCLC, melanoma, RCC, and bladder cancer. The company received breakthrough designation for this last indication. EvaluatePharma puts sales at $2.93 billion by 2020, while the Thomson Reuters Cortellis database puts them at $1.2 billion by 2019. 

MedImmune/AstraZeneca is also in the race with PD-L1 drug MEDI-4736, primarily targeting NSCLC. Also shared at ESMO, a small 18-person study showed a 28% response to MEDI-4736 combined with the CTLA-4-directed antibody tremelimumab. Cortellis projects MEDI-4736 sales at close to $1.1 billion by 2019. 

"We're just at the tip of the iceberg for immuno-oncology, but the enthusiasm is certainly warranted because of the kinds of responses and the tumors being opened up," says Fernandez. "The field is about as exciting and confusing as you could possibly imagine." (Más)

Anish Shindore* se "en red_a" con NOVARTIS/ "The competition is still in the product, not the social media page."

"The Spanish people are very passionate and outspoken; they want to express their opinions," Anish explains pragmatically, 

"They a very good country when it comes to using a medium that is already out there. However, starting a new medium is not something for which they are well known. Adaptation is very fast, but uptake is very slow. For example Facebook really only gained momentum 3-4 years ago in Spain, yet now seemingly everyone is using it." 

"Novartis aspires to be the most innovative pharmaceutical company. But that is not really about 'digital' or 'social media'. R&D in medicines has to be our focus, not by innovating with some shiny new mobile app. Innovation is part of our culture, but it has to start with having good drugs. My role is to help us adapt to what the market is doing and add the possibility of interaction with customers." 

"For us and others, we are still getting too excited with social. Sure, it is the present aspect of interest, however history shows there will be equally be an opposing 'anti-social' movement in the next few years. We should ensure we do not get too far away from our core business; that is, what we do best."

Ver:

Social media in Spain; core to pharmaceutical innovation? / Paul Grant


  (*) Anis Shindore eMarketing / Digital Commercialization Head for Novartis in Spain

I Estudio de reputación en Esalud de la Industria Farmacéutica 2014

...el presente documento pretende analizar la evolución de la relación a través de la eSalud de los laboratorios farmacéuticos con su entorno. Para ello se ha realizado un estudio comparativo entre las distintas empresas farmacéuticas que operan dentro del ámbito nacional obteniendo datos estadísticos que evalúan el estado actual de grado de penetración de soluciones de aplicación de las TIC en el sector. De dicho estudio se obtienen unas conclusiones y se esboza el futuro que se prevé en base a las tendencias del mercado. También se compara el uso de la eSalud en otros actores del sector sanitario, para poder valorar el grado de madurez de las soluciones en la industria farmacéutica.

En general podemos concluir que el sector farmacéutico está usando en muy poca medida las nuevas posibilidades que este campo ofrece para potenciar negocio o actividades relacionadas. Si bien ha habido una inmersión en lo que podemos llamar la Web 1.0, es decir, la presencia de los laboratorios en Internet es algo completamente asumido y normal, no ha habido una evolución posterior llamativa. Encontramos grandes contrastes entre las páginas Web analizadas, desde las más punteras y actualizadas hasta muchas que necesitan dar un salto hacia las posibilidades actuales. Lo mismo ocurre con las páginas desarrolladas para colectivos específicos, médicos, farmacéuticos, pacientes o investigadores: se han centrado en la gestión de contenidos y no han evolucionado, en la mayoría de los casos, al siguiente nivel. Los contrastes de calidad son también acusados.(Más/Descargar)

Top 10 Pharma Companies using Social Media / IMS Healtt Social Media Report

Based on the IMS Health Social Media Report which is released by the beginning of 2014 , Among the top 50 pharmaceutical companies, half do not engage with consumers or patients through social media on healthcare-related topics. 

IMS Health ranked the top 10 Pharmaceutical companies on using Social Media as follow :

1. Johnson & Johnson 
2. GlaxoSmithkline 
3. Novo Nordisk 
4. Pfizer 
5. Novartis 
6. Boehringer Ingelheim 
7. Bayer 
8. Merck & Co 
9. AstraZeneca
10. UCB

IMS Health used several indices to rank those companies like :

• Reach index : which is the measure of the absolute number of listeners and the index is based on the number of people reached by each channel through likes, shares and re-tweets. 


• Relevance Index : Which is the measures whether people found posts or content relevant and/or useful, and the index is based on the extent to which content is being shared and forwarded across social networks.


• Relationship Index : A measure of interaction - the back and forth of conversation - and a measure of company and consumer or patient integration. f
  
  The relationship index measures the level of interaction between a company and those who post, reply or otherwise interact with the company’s postings.

• Johnson & Johnson is the most social Pharma company in the world followed by GlaxoSmithKline and Pfizer. 
• Johnson & Johnson is the most mentioned brand on social media. 
• Bayer has the most active and the highest fan base on Facebook. As a result Bayer is ranked no. 1 on Facebook among all competitors. 
• Pfizer scored the highest on Twitter.

Más

Humor:..es lunes: #Sanichollo/Salud "low cost"...

Creatividad Sir Richards condoms : “Have sex, save lives.”

“I’m doing my part to help the world. That’s what we do here at Sir Richard’s. For every condom you purchase, we donate one to a developing country. So far, Sir Richard’s has donated over 2.5 million condoms.”

Buy One, Give One Sir Richard’s Impact Sir Richard's was founded in 2009 by a team of socially conscious entrepreneurs and designers. Sir Richard’s condoms were launched in the market in January 2011. The company’s founders believed that the time was ripe to breathe life into a very dated product category controlled by one or two companies that hadn’t innovated in decades. 

At the core of their purpose, the founders also wanted to connect product sales and company growth with a direct global humanitarian impact. As such, since its founding, for every condom Sir Richard’s sells, we donate one condom to a community in need. To date, we have donated millions of condoms as part of our Buy One, Give One program. 

Over our first few years, Sir Richard’s primarily partnered with Partners In Health as a distribution partner to get condoms safely and effectively to Haiti. These condoms have been made available at no charge through PIH's clinics. 

Partners In Health ranks as one of the largest nongovernmental health care providers in Haiti with over 5,000 employees and more than 2.6 million patient visits at its clinics in 2008. It launched the world's first program to provide free, comprehensive HIV care and treatment in an impoverished setting, and as part of its prevention efforts distributes (on average) two million condoms per year. 

In early 2014, the company initiated its “Nominate a Cause” program to crowdsource Buy One, Give One donation recipients. Sir Richard’s customers can now nominate a cause they care about to receive donated condoms.(Más)